In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Product Liability: When Bad Things Happen to Good Companies

Executive Summary

Guidant's problems with its ICD business, coming in the midst of its merger negotiations with Johnson & Johnson, highlighted the impact that product recalls and problems can have for companies. Generally speaking, product liability is becoming a bigger issue for medical device companies as consumers grow more skeptical that the government is protecting their interests where product safety is concerned.

You may also be interested in...



CMS News is Good for Troubled Markets

There was probably no group more relieved than the makers of implantable cardioverter defibrillators (ICDs) to see the Centers for Medicaid and Medicare Services (CMS) in August drastically modify its proposal to slash hospital reimbursement. The change is as a result of effective lobbying from the medical device community as well as the hospital industry, and is welcome news to all high-end device makers.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel